The investigation of the antipsychotic effects of adding d-penicillamine to risperidone on schizophrenia.

The investigation of the antipsychotic effects of adding d-penicillamine to risperidone on the positive and negative symptoms of schizophrenia.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20131007014928N6

Enrollment

Registered

2019-01-10

Start date

2017-09-21

Completion date

Unknown

Last updated

2019-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

schizophrenia. ?????????

Interventions

Intervention 1: 16 patients in the case group were treated with oral risperidone (8-6 mg) per day for 6 weeks as a neuroleptic drug with d-penicillamine (1000 mg / day) and pyridoxine (100 mg / day).

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patient with schizophrenia that did not receive any antipsychotics during the last week.

Exclusion criteria

Exclusion criteria: Patient did not suffer from Wilson's or other metabolic diseases

Design outcomes

Primary

Measure	Time frame
Positive and negative symptoms. Timepoint: weekly. Method of measurement: PANSS.	—

Secondary

Measure	Time frame
Adverse effects. Timepoint: weekly until 6 weeks. Method of measurement: Simpson Angus Scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Mehdi Pourasghar

Mazandaran University of Medical Science.

me_pourasghar@yahoo.com+98 11 3328 6868

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026